Advertisement
A vs TMO
Which Stock Would AI Choose? Agilent Technologies (A) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- Agilent Technologies (A) and Thermo Fisher Scientific (TMO) operate in the life sciences tools and diagnostics sector, with A focusing on analytical instruments and TMO offering a broader portfolio including services and biopharma solutions.
- Recent market activity shows A delivering stronger year-to-date returns around 17.6% compared to TMO’s approximately 9%, alongside notable monthly gains for both amid sector recovery.
- TMO reported second-quarter revenue of $11.99 billion with 5% organic growth, supported by a $1.1 billion divestiture of its microbiology business.
- A prepares for third-quarter earnings on August 26 with projected EPS of $1.48 and revenue of $1.84 billion, following analyst upgrades such as Morgan Stanley raising its price target.
- Both companies exhibit positive momentum from life sciences demand, though A shows relatively higher short-term technical strength while TMO benefits from scale and diversified end markets.
- Sector exposure to biopharma and research spending creates shared tailwinds, with trade-offs in growth consistency versus operational breadth.
Introduction
Agilent Technologies (A) and Thermo Fisher Scientific (TMO) represent two prominent players in the life sciences and analytical instrumentation space, making them relevant for investors seeking exposure to healthcare innovation and research tools. This comparison appeals to portfolio managers, sector specialists, and traders evaluating relative performance, business model differences, and positioning within a recovering biopharma environment. By examining recent price behavior, operational developments, and market sentiment, the analysis highlights contrasts that can inform decisions on diversification or tactical allocation without favoring either security.
Agilent Technologies (A) Overview and Recent Performance
Agilent Technologies (A) provides analytical instruments, diagnostics, and services primarily for life sciences, applied markets, and diagnostics. In recent weeks, the stock has demonstrated resilience with gains exceeding 11% over the past month and year-to-date returns near 17.6%. Performance has been supported by anticipated third-quarter results and positive analyst commentary, including price target increases. Broader life sciences demand and upcoming catalysts have contributed to improved sentiment, positioning the shares favorably relative to broader market benchmarks in the near term.
Thermo Fisher Scientific (TMO) Overview and Recent Performance
Thermo Fisher Scientific (TMO) delivers a comprehensive suite of life sciences solutions, including instruments, reagents, and contract development services for biopharma and research clients. Recent market activity reflects steady recovery, with organic revenue growth of 5% in the second quarter and overall revenue reaching $11.99 billion. The company completed a $1.1 billion sale of its microbiology unit, which has helped streamline operations. Year-to-date returns approximate 9%, with monthly advances near 20% amid improving sector conditions and diversified end-market exposure.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots optimized for prevailing market conditions. The platform hosts hundreds of AI Trading Bots that execute strategies across thousands of tickers, yet only those demonstrating superior alignment with current trends, robust risk metrics, and consistent historical performance earn placement in this section. Available bots span diverse trading styles, timeframes, and performance profiles, with many exhibiting win rates in the 55-75% range and varying drawdown characteristics depending on their underlying algorithms. Readers interested in exploring automated strategies can visit the Trending AI Robots page for further details.
Head-to-Head Comparison
Agilent Technologies (A) maintains a more specialized focus on analytical chemistry and diagnostics, offering higher operating margins in select segments but narrower revenue diversification than Thermo Fisher Scientific (TMO). TMO’s scale enables broader exposure across biopharma services and global research markets, providing stability during cyclical slowdowns. Recent momentum favors A with stronger year-to-date and short-term technical readings, while TMO benefits from organic growth visibility and post-divestiture focus. Risk factors include A’s sensitivity to instrument capital spending cycles versus TMO’s larger balance sheet and integration complexities from acquisitions. Sector sentiment remains constructive for both amid biopharma recovery, though A’s smaller size may amplify volatility relative to TMO’s established market position.
Tickeron AI Verdict
Based on observable factors including trend consistency, relative technical strength, and near-term catalysts, Tickeron’s AI models currently assign a modest preference to Agilent Technologies (A) over Thermo Fisher Scientific (TMO). A exhibits stronger short-term momentum and analyst support, potentially offering more favorable risk-reward characteristics in the current environment, though outcomes remain probabilistic and subject to evolving market data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a Hold and TMO is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 2 FA rating(s) are green whileTMO’s FA Score has 3 green FA rating(s).
- A’s FA Score: 2 green, 3 red.
- TMO’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 3 TA indicator(s) are bullish while TMO’s TA Score has 4 bullish TA indicator(s).
- A’s TA Score: 3 bullish, 5 bearish.
- TMO’s TA Score: 4 bullish, 5 bearish.
Price Growth
A (@Medical Specialties) experienced а -1.94% price change this week, while TMO (@Medical Specialties) price change was -1.35% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +5.68%. For the same industry, the average monthly price growth was +11.00%, and the average quarterly price growth was +34.25%.
Reported Earning Dates
A is expected to report earnings on Nov 30, 2026.
TMO is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Medical Specialties (+5.68% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| A | TMO | A / TMO | |
| Capitalization | 42.5B | 227B | 19% |
| EBITDA | 2.04B | 12B | 17% |
| Gain YTD | 11.535 | 6.136 | 188% |
| P/E Ratio | 29.76 | 33.03 | 90% |
| Revenue | 7.37B | 46.3B | 16% |
| Total Cash | 1.76B | 4.06B | 43% |
| Total Debt | 3.95B | 42.5B | 9% |
A | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 95 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 11 Undervalued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 80 | |
SMR RATING 1..100 | 45 | 60 | |
PRICE GROWTH RATING 1..100 | 22 | 15 | |
P/E GROWTH RATING 1..100 | 43 | 28 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (11) in the Biotechnology industry is in the same range as TMO (13) in the Medical Specialties industry. This means that A’s stock grew similarly to TMO’s over the last 12 months.
TMO's Profit vs Risk Rating (80) in the Medical Specialties industry is in the same range as A (100) in the Biotechnology industry. This means that TMO’s stock grew similarly to A’s over the last 12 months.
A's SMR Rating (45) in the Biotechnology industry is in the same range as TMO (60) in the Medical Specialties industry. This means that A’s stock grew similarly to TMO’s over the last 12 months.
TMO's Price Growth Rating (15) in the Medical Specialties industry is in the same range as A (22) in the Biotechnology industry. This means that TMO’s stock grew similarly to A’s over the last 12 months.
TMO's P/E Growth Rating (28) in the Medical Specialties industry is in the same range as A (43) in the Biotechnology industry. This means that TMO’s stock grew similarly to A’s over the last 12 months.
| A | TMO | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 58% | 4 days ago 59% |
| Stochastic ODDS (%) | 4 days ago 61% | 4 days ago 59% |
| Momentum ODDS (%) | 4 days ago 56% | 4 days ago 59% |
| MACD ODDS (%) | 4 days ago 51% | 4 days ago 54% |
| TrendWeek ODDS (%) | 4 days ago 63% | 4 days ago 61% |
| TrendMonth ODDS (%) | 4 days ago 60% | 4 days ago 62% |
| Advances ODDS (%) | 12 days ago 60% | 5 days ago 62% |
| Declines ODDS (%) | 7 days ago 63% | 7 days ago 63% |
| BollingerBands ODDS (%) | 4 days ago 71% | 4 days ago 59% |
| Aroon ODDS (%) | 4 days ago 64% | 4 days ago 58% |
Advertisement
A and
Correlation & Price change
A.I.dvisor indicates that over the last year, A has been closely correlated with TMO. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if A jumps, then TMO could also see price increases.
TMO and
Correlation & Price change
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.
| Ticker / NAME | Correlation To TMO | 1D Price Change % | ||
|---|---|---|---|---|
| TMO | 100% | -0.75% | ||
| A - TMO | 74% Closely correlated | +0.59% | ||
| DHR - TMO | 73% Closely correlated | -1.60% | ||
| RVTY - TMO | 70% Closely correlated | -0.31% | ||
| IQV - TMO | 69% Closely correlated | -1.42% | ||
| BRKR - TMO | 67% Closely correlated | -1.53% | ||
More | ||||